New University of Cincinnati research discovered a unique class of medications that act as blood thinners by inhibiting an enzyme in the genes of tick saliva.
The research focused on novel direct thrombin inhibitors (DTI) from tick salivary transcriptomes, or messenger RNA molecules expressed by an organism. The result is the development of new anticoagulant medications that can be used to treat patients with a variety of coronary issues, including heart attacks. The study was published in Nature Communications.
